Dendritic cell-based vaccine prolongs survival and time to next therapy independently of the vaccine cell number

In 2009, new EU legislation regulating advanced therapy medicinal products (ATMPs), consisting of gene therapy, tissue engineering and cell-based medicines, was introduced. Although less than 20 ATMPs were authorized since that time, the awarding of the Nobel Prize for Physiology or Medicine in 2018...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawlina, Simon, Chowdhury, Helena H., Smrkolj, Tomaž, Zorec, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864901/
https://www.ncbi.nlm.nih.gov/pubmed/35197090
http://dx.doi.org/10.1186/s13062-022-00318-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864901/
https://www.ncbi.nlm.nih.gov/pubmed/35197090
http://dx.doi.org/10.1186/s13062-022-00318-w

Ejemplares similares